Literature DB >> 10233861

Morphological, histochemical, immunohistochemical, and ultrastructural characterization of tumors and dysplastic and non-neoplastic lesions arising in BK virus/tat transgenic mice.

G Altavilla1, C Trabanelli, M Merlin, A Caputo, M Lanfredi, G Barbanti-Brodano, A Corallini.   

Abstract

To study the role in AIDS pathogenesis of the human immunodeficiency virus type 1 (HIV-1) Tat protein, a transactivator of viral and cellular genes, we generated transgenic mice with a recombinant DNA containing BK virus (BKV) early region and the HIV-1 tat gene, directed by its own promoter-enhancer. DNA hybridization revealed that the transgene is stably maintained in all organs of transgenic mice as a tandem insertion in a number of copies ranging from 5 to 20 per cell. In addition, tat and BKV RNA were expressed in all tissues. Transgenic mice developed three types of lesions: 1) tumors, 2) hyperplastic and dysplastic lesions, and 3) non-neoplastic lesions. Tumors of different histotypes, such as lymphomas, adenocarcinomas of skin glands, leiomyosarcomas, skin squamous cell carcinomas, hepatomas, hepatocarcinomas, and cavernous liver hemangiomas, developed in 29% of transgenic animals. The majority of tumors were malignant, invasive, and producing metastases. Conversely, tumors of only two histotypes (lymphomas and adenocarcinomas of skin glands) appeared in control mice. Hyperplastic and dysplastic lesions were more frequent in transgenic than in control mice and involved the skin or its adnexes, the liver and the rectum, indicating multiple targets for the activity of the transgene. Pyelonephritis, frequently complicated with hydronephrosis, inflammatory eye lesions, and amyloid depositions represented the most frequent non-neoplastic lesions detected in transgenic mice. Many of the pathological findings observed in this animal model are comparable to similar lesions appearing in AIDS patients, suggesting a relevant role for Tat in the pathogenesis of such lesions during the course of AIDS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233861      PMCID: PMC1868602          DOI: 10.1016/S0002-9440(10)65375-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  41 in total

1.  Transcellular transactivation by the human immunodeficiency virus type 1 tat protein.

Authors:  D E Helland; J L Welles; A Caputo; W A Haseltine
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

Review 2.  The biochemistry of AIDS.

Authors:  Y N Vaishnav; F Wong-Staal
Journal:  Annu Rev Biochem       Date:  1991       Impact factor: 23.643

Review 3.  Cancer in acquired immunodeficiency syndrome: an epidemiological assessment.

Authors:  R J Biggar
Journal:  Semin Oncol       Date:  1990-06       Impact factor: 4.929

Review 4.  Role of human immunodeficiency virus type 1 and other viruses in malignancies associated with acquired immunodeficiency disease syndrome.

Authors:  K J Cremer; S B Spring; J Gruber
Journal:  J Natl Cancer Inst       Date:  1990-06-20       Impact factor: 13.506

5.  Endemic Kaposi's sarcoma in human immunodeficiency virus type 1-seronegative persons: demonstration of retrovirus-like particles in cutaneous lesions.

Authors:  K Rappersberger; E Tschachler; E Zonzits; R Gillitzer; A Hatzakis; A Kaloterakis; D L Mann; T Popow-Kraupp; R J Biggar; R Berger
Journal:  J Invest Dermatol       Date:  1990-10       Impact factor: 8.551

6.  Characterization of BK virus variants rescued from human tumours and tumour cell lines.

Authors:  M Negrini; P Rimessi; C Mantovani; S Sabbioni; A Corallini; M A Gerosa; G Barbanti-Brodano
Journal:  J Gen Virol       Date:  1990-11       Impact factor: 3.891

7.  BK virus T antigens induce kidney carcinomas and thymoproliferative disorders in transgenic mice.

Authors:  S A Dalrymple; K L Beemon
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

8.  The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice.

Authors:  J Vogel; S H Hinrichs; R K Reynolds; P A Luciw; G Jay
Journal:  Nature       Date:  1988-10-13       Impact factor: 49.962

9.  Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients.

Authors:  B Ensoli; G Barillari; S Z Salahuddin; R C Gallo; F Wong-Staal
Journal:  Nature       Date:  1990-05-03       Impact factor: 49.962

10.  Temporal trends in the incidence of non-Hodgkin's lymphoma and selected malignancies in a population with a high incidence of acquired immunodeficiency syndrome (AIDS)

Authors:  M E Harnly; S H Swan; E A Holly; A Kelter; N Padian
Journal:  Am J Epidemiol       Date:  1988-08       Impact factor: 4.897

View more
  5 in total

Review 1.  Burkitt's lymphoma: new insights into molecular pathogenesis.

Authors:  C Bellan; S Lazzi; G De Falco; A Nyongo; A Giordano; L Leoncini
Journal:  J Clin Pathol       Date:  2003-03       Impact factor: 3.411

2.  Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene.

Authors:  G Altavilla; A Caputo; M Lanfredi; C Piola; G Barbanti-Brodano; A Corallini
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 3.  Functional roles of HIV-1 Tat protein in the nucleus.

Authors:  Yana R Musinova; Eugene V Sheval; Carla Dib; Diego Germini; Yegor S Vassetzky
Journal:  Cell Mol Life Sci       Date:  2015-10-27       Impact factor: 9.261

4.  Inflammatory papillomatous hyperplasia and epidermal necrosis in a transgenic rat for HIV-1.

Authors:  Filiberto Cedeno-Laurent; Joseph Bryant; Rita Fishelevich; Odell D Jones; April Deng; Maria L Eng; Anthony A Gaspari; J Roberto Trujillo
Journal:  J Dermatol Sci       Date:  2008-11-11       Impact factor: 4.563

5.  Kaposi's Sarcoma Lesion Progression in BKV-Tat Transgenic Mice Is Increased by Inflammatory Cytokines and Blocked by Treatment with Anti-Tat Antibodies.

Authors:  Egidio Brocca-Cofano; Cecilia Sgadari; Orietta Picconi; Clelia Palladino; Antonella Caputo; Barbara Ensoli
Journal:  Int J Mol Sci       Date:  2022-02-14       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.